John Burke, MD, comments on venetoclax-associated toxicities and practical advice on improving safety when combined with obinutuzumab for chronic lymphocytic leukemia; venetoclax combined with ibrutinib is of particular interest based on early efficacy data.
Website: www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive